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Background: The 6-Minute Walk Test (6MWT) is a widely used measurement of functional exer-
cise capacity in chronic lung disease. While exercise intolerance has been identified in patients
with bronchiectasis, the clinical determinants of the 6MWT in this population have not been
examined. The aim of this study was to 1) establish the relationship between the 6-Minute
Walk Distance (6MWD), disease severity and Health-Related Quality of Life (HRQOL) and 2)
identify predictors of exercise tolerance in adults with bronchiectasis.
Methods: The 6MWT was performed in 27 patients with bronchiectasis (mean [SD] FEV1 73.9%
predicted [23.4]). Disease severity was assessed using spirometry and HRCT scoring while
HRQOL was evaluated using the St George’s Respiratory Questionnaire (SGRQ) and the Short-
Form 36 (SF-36). The relationships were evaluated using correlation and multiple regression.
Results: The 6MWD correlated positively with FVC (rZ 0.52, p< 0.01), generations of bronch-
opulmonary divisions (rsZ 0.38, p< 0.05) and SF-36 physical summary (rZ 0.71, p< 0.001)
while a negative correlation was observed between all domains of the SGRQ (all correlations
r> 0.5, p< 0.001). Multiple regression analysis indicated that the SGRQ activity, symptom
scores and generations of bronchial divisions involved were identified as independent predic-
tors of the 6MWD, explaining 76% of the variance.t of Physiotherapy, The Alfred Hospital, Commercial Road, Melbourne, 3004 Victoria, Australia.
62702.
fred.org.au (A.L. Lee).
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6-Minute Walk Test in bronchiectasis 781Conclusions: Measures of HRQOL demonstrated a stronger association with the 6MWD
compared to physiological measures of disease severity in patients with predominantly mild
to moderate bronchiectasis.
Crown Copyright ª 2008 Published by Elsevier Ltd. All rights reserved.Introduction
Bronchiectasis not attributable to Cystic Fibrosis (CF) is
a chronic respiratory condition, characterised by cough and
sputum production1e3 together with physical fatigue and
reduced exercise tolerance.4,5 Postulated causes of dimin-
ished exercise capacity include dyspnoea secondary to
dynamic hyperinflation,6 altered respiratory mechanics and
decreased skeletal muscle bulk.4,7 However, there has been
limited evaluation of physical function in patients with
bronchiectasis and the influence of respiratory disease
severity and extent of bronchiectasis on exercise capacity
is unclear.
The 6-Minute Walk Test (6MWT) is a widely used measure
of functional status, as well as being a predictor of prog-
nosis across a multitude of respiratory conditions.8e12
Although these clinical applications suggest that this simple
measurement may also be a reflection of the pulmonary
and functional status of patients with bronchiectasis,
evaluation of the 6MWT in this population has been limited.
While other measures of exercise capacity have been linked
to Health-Related Quality of Life (HRQOL),4 the relationship
between the 6-Minute Walk Distance (6MWD) and HRQOL in
bronchiectasis is unclear. Furthermore, the role of physio-
logical markers of disease severity or HRQOL as clinical
predictors of the 6MWD in patients with bronchiectasis has
not been evaluated. In this pilot study, we aimed to 1)
examine the relationship between lung disease severity,
HRQOL and the 6MWD and 2) to identify those clinical
variables predicting functional exercise capacity in a group
of patients with bronchiectasis.Methods
Subjects
This is a within-subject correlational study of a group of
adults who were recruited from an outpatient clinic of
a tertiary hospital for a prospective evaluation of gastro-
oesophageal reflux in non-CF bronchiectasis. A diagnosis of
bronchiectasis was confirmed by High-Resolution Computed
Tomography (HRCT). All participating subjects were non-
smokers. Exclusion criteria were a concurrent diagnosis of
Chronic Obstructive Pulmonary Disease (COPD), based on
clinical presentation, including smoking history13 together
with a demonstration of emphysema on HRCT. Patients
were also excluded if they had a clinical history of asthma
and/or an increase in FEV1 by 200 ml or greater than or
equal to 12% following bronchodilator therapy14 or confir-
mation of interstitial lung disease based on diagnostic
guidelines.15 A total of five patients were prescribed
bronchodilator therapy (salbutamol) while five were using
long-term antibiotics at the time of the study. Clinicalstability was required for all patients and was defined as
the absence of clinical deterioration beyond normal daily
variations without increasing need for usual or rescue
medication during the four weeks prior to evaluation.16
Approval for this project was obtained from institutional
HREC and written informed consent was obtained from
each patient.
Procedure
The extent of bronchiectasis according to HRCT, measured
within 12 months of participation in the study was evalu-
ated by a consultant radiologist using the scoring system
proposed by Bhalla et al.17 The aetiology of bronchiectasis
was determined through review of clinical records detailing
investigations of predisposing factors, including immuno-
globulin levels with subclasses, ciliary function (primary
ciliary dyskinesia), Allergic Bronchopulmonary Aspergillosis
(ABPA) and post-infective origin. In the event of no iden-
tifying aetiology, the cause was classified as idiopathic.
Gender, age and Body Mass Index (BMI) were collated for
each patient. Lung function tests (spirometry) using the
Medgraphics Corporation Lung Function testing system
(Minnesota, USA) and Software Breeze Suite V6.2A and 6.2C
were performed on the day prior to exercise testing
according to the ATS guidelines.18
HRQOL was recorded using the St George’s Respiratory
Questionnaire (SGRQ)19 and the Short-Form 36 (SF-36).20
The SGRQ is a disease-specific tool composed of 50 items
assessed by three subscales, symptoms, impact and activity
as well as a total score.21 The score of each domain as well
as the total score is calculated as a function of the item
scores, with lower scores indicating better HRQOL and
higher scores indicating worse HRQOL, ranging from 0 to
100. The SGRQ has been validated in patients with bron-
chiectasis.4 The SF-36 is a generic measure which evaluates
HRQOL over eight domains.20 Based on the scores in each of
these domains, physical and mental summary scores were
calculated. Poor HRQOL is indicted by a lower score on the
SF-36.
Each patient completed two 6MWTs according to
a standardised protocol.22 The test was conducted along an
enclosed 30 m corridor and patients were instructed to
walk at their own pace but to cover as much ground as
possible within 6 min. Standardised encouragement was
provided during the test. Oxygen saturation (SpO2) was
monitored throughout the walk. The greatest distance out
of the two tests was recorded as the 6MWD.
Data management
Statistical analyses were performed using SPSS for Windows
version 15.0. Data are expressed as means (SD). The rela-
tionship between variables was examined using Pearson’s
Table 2 Severity of bronchiectasis according to HRCT.
HRCT scoring classifications N (%)
Bronchiectasis severity Mild 15 (56)
Moderate 10 (37)
Severe 2 (7)
Peribronchial thickening Mild 27 (100)
Extent of bronchiectasis 1e5 8 (30)
6e9 9 (33)
>9 10 (37)
Extent mucus plugging Absent 15 (56)
1e5 10 (37)
6e9 2 (7)
Sacculations Absent 25 (93)
1e5 2 (7)
Generations Up to 4th 2 (7)
Up to 5th 10 (37)
Up to 6th 15 (56)
Bullae Absent 26 (96)
>5 1 (4)
Emphysema Absent 27 (100)
Collapse/consolidation Absent 12 (44)
Subsegmental 8 (30)
Segmental/lobar 7 (26)
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782 A.L. Lee et al.correlation coefficient or Spearman’s rho depending on the
distribution of the data. Differences between groups based
on gender were analysed using Student’s t-test. Multivar-
iate linear regression analysis was conducted to determine
predictors of the 6MWD, with variables found to be signifi-
cant at p< 0.05 on univariate analysis included in the
model. Where multi-collinearity was apparent, the variable
with the highest significance level on univariate analysis
was included. Statistical significance was accepted at an
alpha <0.05.
Results
Patient characteristics
A total of 27 patients (16 female) with bronchiectasis
participated in this study. Demographic data and baseline
lung function are outlined in Table 1, with only two patients
awaiting lung transplantation at the time of the study. The
aetiology of bronchiectasis was attributed to six possible
causes. These included childhood or adult illnesses
including pertussis, measles or pneumonia in 13 patients
(46.7%). Idiopathic bronchiectasis was evident in 10
patients (33%), while primary hypogammaglobulinaemia
was the identified source in two patients (7%). Young’s
syndrome, ABPA and diffuse panbronchiolitis were under-
lying aetiologies in one patient each.
Table 2 shows the severity of bronchiectasis based on
HRCT scoring.17 The severity of bronchiectasis was
predominantly mild to moderate (93%) with mild peri-
bronchial thickening in all patients. While the majority of
patients (70%) had at least six bronchopulmonary
segments involved, evidence of mucus plugging was
present in only 44% of subjects. Most patients demon-
strated involvement of at least the 5th generation of
bronchial division (93%). Accompanying collapse or
consolidation was found in the subsegmental or segmental
region in 56% of patients.
Fig. 1 depicts a histogram of the 6MWD, which ranged
from 300 to 750 m. No patient required ambulatory oxygen
therapy (i.e. SpO2< 85% during the test). The mean (SD)
SGRQ total score was 41.5 (16.8). The mean (SD) SF-36
physical and mental summary scores were 38.5 (11.2) and
48.3 (8.7) respectively. There was a wide range of HRQOLTable 1 Demographic data for subjects with bronchiec-
tasis (nZ 27).
Demographic factor Mean (SD) 95% CI
Age (years) 54.4 (13.8) 40.8e74.7
BMI (kg/m2) 26.6 (5.8) 21.8e39.4
FEV1 (L) 2.3 (0.9) 1.6e4.0
FEV1% predicted 73.9 (23.4) 52.3e108.5
FVC (L) 3.4 (1.1) 2.8e5.3
FVC % predicted 89.4 (20.2) 78.3e126.9
6MWD (m) 547.4 (115.8) 430.5e725.6
BMIZ Body Mass Index; FEV1Z Forced Expiratory Volume in
one second; FVCZ Forced Vital Capacity; 6MWDZ 6-Minute
Walk Distance.scores for both SGRQ and SF-36, with evidence of optimal
HRQOL (lowest possible score) according to the SGRQ
symptom and activity scores in some patients. There was
a significant correlation between all three components of
the SGRQ (symptoms, activity and impact) and the SF-36
physical summary (p< 0.05 for all correlations).
Relationships between clinical features and
exercise tolerance
Females hadpoorer exercise tolerance compared tomales on
the 6MWT (mean difference of 96 m, 95% CI -182.1 to -9.1 m,
pZ 0.023). There was no relationship between the 6MWD,
age or BMI (Table 3). Spirometric measures of disease
severity correlated moderately with the 6MWD, suggesting
that a higher exercise tolerance was present in those with6MWD (m)
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Figure 1 Histogram demonstrating the distribution of the
6MWD.
Table 3 Correlations between 6MWD, clinical variables
and HRQOL.
6MWDa p value
Age (years) 0.324 pZ NS
BMI (kg/m2) 0.241 pZ NS
FEV1 % pred 0.485 pZ 0.035
FVC % pred 0.513 pZ 0.006
Severity of bronchiectasis 0.024 pZ NS
Extent of bronchopulmonary
segments involved
0.34 pZ 0.083
Extent of mucus plugging 0.086 pZ NS
Sacculations 0.061 pZ NS
Generations of bronchial
divisions involved
0.382 pZ 0.049
Collapse/consolidation 0.039 pZ NS
SGRQ symptom score 0.642 p< 0.000
SGRQ activity score 0.768 p< 0.000
SGRQ impact score 0.678 p< 0.000
SGRQ total score 0.820 p< 0.000
SF-36 physical summary score 0.709 p< 0.000
SF-36 mental summary score 0.059 pZ NS
a Data expressed as Pearson’s r or Spearman’s rho; NSZ Non-
significant, 6MWDZ 6-Minute Walk Distance, BMIZ Body Mass
Index; FEV1Z Forced Expiratory Volume in one second;
FVCZ Forced Vital Capacity; SGRQZ St George’s Respiratory
Questionnaire, SF-36Z Short-Form 36.
6-Minute Walk Test in bronchiectasis 783less airway obstruction (Table 3). However, only a weak
relationship between generations of bronchial divisions and
the 6MWD was demonstrated, with a higher 6MWD in those
with more generations involved. No other relationship
between severity of bronchiectasis and the 6MWD was
evident. The 6MWD was strongly associated with all domains
of the SGRQ and the SF-36 physical summary (Table 3) with
the strongest relationships exhibited with SGRQ activity
score and total score. Overall, exercise tolerance demon-
strated a stronger correlation to HRQOL than physiological
measures of lung function or disease severity.
A multivariate linear regression analysis was completed
using those factors found to be significant by univariate
analysis, including FVC% predicted, generations of bronchial
divisions and SGRQ symptom, activity and impact scores. The
SGRQ symptom and activity scores and generations of bron-
chial divisions were identified as independent predictors of
the 6MWD, in total explaining 76% of the variance. A lower
6MWDwasassociatedwith higher SGRQ symptomandactivity
scores (which indicated worse HRQOL) and fewer genera-
tions of bronchial divisions on HRCT.
Discussion
To our knowledge, this is the first study to describe the
relationship between the 6MWD and clinical variables
including disease severity and HRQOL in a group of patients
with predominantly mild to moderate bronchiectasis. The
6MWD demonstrated a stronger relationship with HRQOL
domains compared to physiological measures of lung
disease severity and limited association with structural
abnormalities of bronchiectasis. HRQOL measuresincorporating symptom severity and activity limitations
were stronger independent predictors of the 6MWD
compared to physiological parameters.
Increased sputum production and progressive airflow
obstruction have been suggested determinants of reduced
exercise tolerance in bronchiectasis.7,23 Physiologically,
this is supported by evidence of expiratory flow limitation,
which indicates that dynamic hyperinflation and increased
work of breathing are responsible for the strong relation-
ship between dyspnoea and maximal power output
(WRmax).6 Evidence of airflow obstruction measured using
FEV1 and FVC associated with a reduced 6MWD in this study
lends support to this concept and is consistent with a low-
ered aerobic capacity and reduced maximal ventilation in
50% of children with bronchiectasis.24
Despite this moderate relationship, spirometric
measures of disease severity were not independent
predictors of exercise tolerance. This is likely to be due to
the fact that the majority of subjects had relatively well
preserved lung function. It also suggests that other factors
independent of lung function may influence exercise
capacity in this patient population; for example skeletal
muscle dysfunction. Alterations in peripheral muscle
structure with associated impaired oxidative capacity are
key contributors to diminished exercise tolerance in
patients with COPD.25,26 Exertional dyspnoea leads to the
adoption of sedentary lifestyles in patients with COPD,
imposing a cycle of progressive inactivity, deconditioning
and peripheral muscle disuse.27,28 While these systemic
effects may be reflected by the physical fatigue reported in
patients with bronchiectasis,3,5 peripheral muscle function
in this population has not yet been evaluated.
The strong association between the 6MWD, all compo-
nents of the SGRQ and SF-36 physical summary is consistent
with a previous study examining the relationship between
exercise capacity and HRQOL in bronchiectasis.4 In this
study of 111 patients, the distance walked on the Incre-
mental Shuttle Walk Test (ISWT) moderately correlated
with SGRQ symptom (rZ 0.30) and was strongly related to
SGRQ activity (rZ 0.65) and total scores (rZ 0.56).4 The
SGRQ symptom domain is focused on the frequency,
severity and duration of signs and symptoms synonymous
with bronchiectasis while the activity domain concentrates
on the physical restrictions and impairment secondary to
respiratory symptoms.19,21 Exertional dyspnoea and phys-
ical fatigue secondary to chronic infection are recognised
as contributing factors to diminished physical function in
bronchiectasis.2,3,29 On this basis, it was not unexpected
that the SGRQ activity score was a predictor of the 6MWD in
this study. However, our study also supports the view that
respiratory signs and symptoms including cough, sputum,
wheezing and number of acute exacerbations are clinically
relevant when evaluating physical capacity in patients with
mild to moderate bronchiectasis.
The association between structural lung disease deter-
mined by HRCT and exercise tolerance appears to be
limited with only generations of bronchial division involved
a predictor of the 6MWD. This absence of relationship
between HRCT findings and maximal exercise capacity has
been previously described30 and the similar observation in
this study may be due to the inclusion of a small number of
patients (7%) with severe bronchiectasis. The extent of
784 A.L. Lee et al.bronchiectasis also appears to have limited influence on
HRQOL or respiratory symptoms,5,31,32 with significant
correlations restricted to patients with severe and exten-
sive bronchiectasis.31 Although a weak predictor of the
6MWD in this study, the association of a greater 6MWD in
those with more generations of bronchial divisions affected
should be interpreted with caution. The presence of more
than six generations affected in 57% of patients included in
this study may account for this result and requires further
clarification in a larger group of patients. In addition, it is
possible that patients with more extensive bronchiectasis
have been advised to incorporate more exercise as part of
their disease management and therefore have a greater
exercise capacity compared to those with milder disease.
The strong relationship between the 6MWD and HRQOL in
this study implies that strategies to address diminished
exercise capacity through formalised exercise programs in
bronchiectasis may have a similar positive impact on HRQOL.
This effect has been consistently demonstrated following
exercise training in patients with COPD.33 While interna-
tional guidelines for pulmonary rehabilitation support the
inclusion of patientswith bronchiectasis,34,35 there is limited
evidence supporting exercise training. A recent study has
documented improvements in ISWT distance in a group of
patients with bronchiectasis following lower limb endurance
and inspiratory muscle training.36 However, unlike other
populations with respiratory disease, significant improve-
ments in HRQOL were not seen. Further research to confirm
the benefits of recommended exercise prescription outlined
in pulmonary rehabilitation guidelines for patients with
bronchiectasis is required.
This study was limited by the small number of subjects
recruited, the majority of whom demonstrated mild to
moderate bronchiectasis. For this reason, the results
cannot be extrapolated to patients with severe disease.
Identification of additional clinical determinants of the
6MWD in patients with bronchiectasis will require a larger
cohort of subjects across the disease spectrum.
In conclusion, this preliminary study indicates that the
6MWT provides valuable information of the functional
status in a group of patients with mild to moderate bron-
chiectasis, being dependent on an objective assessment of
bronchial divisions involved and a subjective assessment of
HRQOL. A stronger relationship between the 6MWD and
physical symptoms as detected by HRQOL was evident
compared to physiological measures of disease severity.
Management strategies to improve exercise tolerance in
the form of exercise training have the potential to impact
positively on HRQOL in this patient population.Conflict of interest
The authors have no conflicts of interests.
References
1. Barker A. Medical progress: bronchiectasis. New England
Journal of Medicine 2002;346(18):1383e93.
2. Nicotra M, Fivera M, Dale A, Shepherd R, Carter R. Clinical,
pathophysiologic and microbiologic characterisation of bron-
chiectasis in an aging cohort. Chest 1995;108(4):955e61.3. King P, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW.
Characterisation of the onset and presenting clinical features of
adult bronchiectasis. Respiratory Medicine 2006;100:2183e9.
4. Wilson C, Jones P, O’Leary CJ, Cole P, Wilson R. Validation of
the St George’s respiratory questionnaire in bronchiectasis.
American Journal of Respiratory and Critical Care Medicine
1997;156:536e41.
5. O’Leary C, Wilson C, Hansell D, Cole P, Wilson R, Jones P.
Relationship between psychological well-being and lung health
status in patients with bronchiectasis. Respiratory Medicine
2002;96(9):686e92.
6. Koulouris N, Retsou S, Kosmas E, Dimakou K, Malagari K,
Mantzikopoulos G, et al. Tidal expiratory flow limitation,
dyspnoea and exercise capacity in patients with bilateral
bronchiectasis. European Respiratory Journal 2003;21:743e8.
7. Bradley J, Moran F, Greenstone M. Physical training for bron-
chiectasis. Cochrane Database of Systematic Reviews 2002;
(Issue 2). Art No.:CD002166.
8. Cote C, Pinto Plata V, Kasprzyk K, Dordelly L, Celli B. The 6-min
walk distance, peak oxygen uptake and mortality in COPD.
Chest 2007;132:1778e85.
9. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F,
Fujita M. Clinical correlates and prognostic significance of six-
minute walk test in patients with primary pulmonary hyper-
tension. Comparison with cardiopulmonary exercise testing.
American Journal of Respiratory and Critical Care Medicine
2000;161:487e92.
10. Lederer D, Arcasoy S, Wilt J, D’Ovidio F, Sonett J, Kawut S. Six-
minute walk distance predicts waiting list survival in idiopathic
pulmonary fibrosis. American Journal of Respiratory and
Critical Care Medicine 2006;174(6):659e64.
11. Baughman R, Sparkman B, Lower E. Six-minute walk test and
health status assessment in sarcoidosis.Chest2007;132:207e13.
12. Villalba W, Sampaio-Barros P, Pereira M, Cerqueira E, Leme C,
Marques-Neto J, et al. Six-minute walk test for the evaluation
of pulmonary disease severity in scleroderma patients. Chest
2007;131:217e22.
13. Buist A, Roisin R, Anzueto A, Calverley P, Cruz A, DeGuia T,
et al. Global strategy for the diagnosis, management and
prevention of chronic obstructive pulmonary disease. Global
Initiative for Chronic Obstructive Pulmonary Disease (GOLD),
http://www.goldcopd.org; 2007 [accessed 29.02.08].
14. O’Byrne P, Bateman ED, Bousquet J, Clark T, Ohta K,
Paggiaro P, et al. Global initiative for asthma. Global strategy
for asthma management and prevention. Global Initiative for
Asthma (GINA), http://www.ginasthma.com; 2007 [accessed
29.02.08].
15. Wells A, Hirani N, on behalf of the British Thoracic Society
Interstitial Lung Disease Guideline Group, a Subgroup of the
British Thoracic Society Standards of Care Committee in
Collaboration with the Thoracic Society of Australia and New
Zealand and the Irish Thoracic Society. Thorax 2008;63:v1e58.
16. O’Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of
idiopathic bronchiectasis with aerosolized recombinant human
DNase I. rhDNase Study Group. Chest 1998;113(5):1329e34.
17. Bhalla M, Turcios N, Aponte V, Jenkins M, Leitman B,
McCauley D, et al. Cystic fibrosis: scoring system with thin-
section CT. Radiology 1991;179:783e8.
18. Miller M, Hankinson J, Brusasco V, Burgos F, Casaburi R,
Coates A, et al. Standardisation of spirometry. European
Respiratory Journal 2005;26:319e38.
19. Jones P, Quirk F, Baveystock C. The St George’s respiratory
questionnaire. Respiratory Medicine 1991;85(Suppl B):25e31.
20. Ware J, Snow K, Kosinski M, Gandek B. SF-36 health survey.
Manual and interpretation guide. Boston: The Health Institute,
New England Medical Centre; 1993.
21. Jones P, Quirk F, Baveystock C, Littlejohns P. A self-complete
measure of health status for chronic airflow limitation. The St
6-Minute Walk Test in bronchiectasis 785George’s respiratory questionnaire. American Review of
Respiratory Disease 1992;145(6):1321e7.
22. American Thoracic Society. ATS statement: guidelines for the
six-minute-walk test. American Journal of Respiratory and
Critical Care Medicine 2002;166:111e7.
23. Cole P. Inflammation: a two-edged sword-the model of bron-
chiectasis. European Journal of Respiratory Disease 1986;
69(Suppl. 147):6e15.
24. Swaminathan S, Kuppurao K, Somu N, Vijayan V. Reduced
exercise capacity in non-cystic fibrosis bronchiectasis. Indian
Journal of Pediatrics 2003;70:553e6.
25. Gosselink R, Troosters T, DeCramer M. Peripheral muscle weak-
ness contributes to exercise limitation in COPD. American Jour-
nal of Respiratory and Critical Care Medicine 1996;153:976e80.
26. Troosters T, Casaburi R, Gosselink R, DeCramer M. Pulmonary
rehabilitation in chronic obstructive pulmonary disease.
American Journal of Respiratory and Critical Care Medicine
2005;172:19e38.
27. American Thoracic Society and European Respiratory Society.
Skeletal muscle dysfunction in chronic obstructive pulmonary
disease. A Statement of the American Thoracic Society and
European Respiratory Society. American Journal of Respiratory
and Critical Care Medicine 1999;159:S1e40.
28. Agusti A, Noguera A, Sauleda J, Sala E, Pons J, Busquets X.
Systemic effects of chronic obstructive pulmonary disease.
European Respiratory Journal 2003;21:347e60.
29. Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez P,
Soler-Cataluna JJ. Quality-of-life determinants in patientswith clinically stable bronchiectasis. Chest 2005;128:
739e45.
30. Edwards E, Narang I, Li A, Hansell D, Rosenthal M, Bush A.
HRCT lung abnormalities are not a surrogate for exercise
limitation in bronchiectasis. European Respiratory Journal
2004;24:538e44.
31. Eshed I, Minski I, Katz R, Jones P, Priel I. Bronchiectasis:
correlation of high-resolution CT findings with health-related
quality of life. Clinical Radiology 2007;62:152e9.
32. Lynch D, Newell J, Hale V, Dyer D, Corkery K, Fox N, et al.
Correlation of CT findings with clinical evaluations in 261
patients with symptomatic bronchiectasis. AJR American
Journal of Roentgerology 1999;173:53e8.
33. Lacasse Y, Brosseau L, Milne S, Martin S, Wong E, Guyatt G,
et al. Pulmonary rehabilitation for chronic obstructive
pulmonary disease. Cochrane Database of Systematic Reviews
2006;(Issue 2). Art No.:CD003793.
34. Nici L, Donner CF, Wouters EF, Zuwallack R, Ambrosino N,
Bourbeau J, et al. American Thoracic Society/European
Respiratory Society statement on pulmonary rehabilitation.
American Journal of Respiratory and Critical Care Medicine
2006;173:1390e413.
35. Ries A, Gauldoff G, Carlin B, Casaburi R, Emery C, Mahler D,
et al. Pulmonary rehabilitation: joint ACCP/AACVPR Evidence-
based clinical practice guidelines. Chest 2007;131:4e42.
36. Newall C, Stockley RA, Hill SL. Exercise training and inspiratory
muscle training in patients with bronchiectasis. Thorax 2005;
60:943e8.
